WST logo

West Pharmaceutical Services Inc. (WST)

$314.50

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on WST

Market cap

$22.22B

EPS

7.48

P/E ratio

39.7

Price to sales

6.53

Dividend yield

0.28%

Beta

1.184595

Price on WST

Previous close

$317.32

Today's open

$315.41

Day's range

$310.57 - $318.90

52 week range

$206.80 - $330.88

Profile about WST

CEO

Eric M. Green

Employees

10600

Headquarters

Exton, PA

Exchange

New York Stock Exchange

Shares outstanding

70647595

Issue type

Common Stock

WST industries and sectors

Healthcare

Biotechnology & Life Sciences

News on WST

West Pharmaceutical Services, Inc. (WST) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

West Pharmaceutical Services, Inc. (WST) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

news source

Seeking Alpha • Jun 2, 2026

news preview

West Pharma names former Thermo Fisher executive Lagarde as CEO

West Pharmaceutical said on Monday it appointed former Thermo Fisher Scientific executive Michel ​Lagarde as its top boss, effective ‌August 31, succeeding longtime chief Eric Green.

news source

Reuters • Jun 1, 2026

news preview

West Appoints Michel Lagarde to be President and Chief Executive Officer

Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovation EXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that its Board of Directors has appointed Michel Lagarde to be President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors starting August 31, 2026.

news source

PRNewsWire • Jun 1, 2026

news preview

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

West Pharmaceutical Services, Inc.  WST is well positioned for growth, backed by strong demand for HVPs, expanding GLP-1 drug programs and regulatory-driven Annex 1 conversions. However, tariff impacts, destocking in generics and execution challenges at constrained European facilities are concerning.

news source

Zacks Investment Research • May 21, 2026

news preview

West Pharma says fully operational after cyberattack, sees no hit to 2026 forecast

West Pharmaceutical Services said on Wednesday it has ​restored operations across its sites after a cybersecurity attack earlier this ‌month and expects the incident to have no material impact on its 2026 financial outlook.

news source

Reuters • May 20, 2026

news preview

My Top Dividend Growth Picks In Each GICS Sector

I present my top dividend growth picks for each of the 11 GICS sectors, emphasizing discounted valuations and safe, growing dividends. The Sector Winners portfolio outperformed SPY with a 333% five-year return (ex-dividends) and a 0.9% yield; Runners-Up returned 83% with a 1.3% yield. I use a rigorous quality scoring system and sector diversification to minimize dividend cut risks and optimize portfolio resilience.

news source

Seeking Alpha • May 19, 2026

news preview

West Pharma says operations recovering after cyberattack

West Pharmaceutical Services said on Friday its operations were steadily recovering after a cyberattack ​earlier this month disrupted manufacturing and logistics ‌globally.

news source

Reuters • May 15, 2026

news preview

Investors Await Damage Assessment After West Pharmaceutical Cyberattack

West Pharmaceutical Services Inc. (NYSE:WST) on Monday disclosed a material cybersecurity attack on May 7, saying an unauthorized party exfiltrated data and encrypted certain systems.

news source

Benzinga • May 12, 2026

news preview

West Pharmaceutical Services, Inc. (WST) Presents at Bank of America Global Healthcare Conference 2026 Transcript

West Pharmaceutical Services, Inc. (WST) Presents at Bank of America Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • May 13, 2026

news preview

West Pharmaceutical Services, Inc. (WST) Hit a 52 Week High, Can the Run Continue?

West Pharmaceutical (WST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

news source

Zacks Investment Research • May 11, 2026

news preview

¹ Disclosures

Get started with M1

Invest in West Pharmaceutical Services Inc.

Open an M1 investment account to buy and sell West Pharmaceutical Services Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in WST on M1